Clinical trials: Dendritic Cell
Ankylosing Spondylitis
Genetic Susceptibility to Ankylosing Spondylitis (AS) by Functional Genomics Approach
The main objective is to identify in the candidate regions of differentially expressed genes by comparing the transcriptome of dendritic cells derived from circulating monocytes between cases and controls.
- Trial name
- GENOSPA (NCT02525042)
- Where
- France
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atherosclerosis, Restenosis
Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
clinically relevant in stent restenosis occurs in 5-10% of the non-diabetic patients treated with a coronary bare metal stent. Recent research has identified endothelial progenitor cells as well as dendritic cells as components…
- Trial name
- NCT00493597
- Where
- Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Antwerp
Non Small Cell Lung Cancer
Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes
Lung cancer is the worldwide leading cause of cancer death. In France, with 28,000 new cases per year, lung cancer is the 4th in terms of incidence but remains the leading cause of cancer death.
- Trial name
- CSET 1437 (NCT01159288)
- Testing
- Dex2
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Multiple Myeloma
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
- Trial name
- NCT00186316
- Testing
- Idiotype-pulsed allogeneic dendritic cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Follicular Lymphoma
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin's lymphoma and is often diagnosed in advanced incurable stage.
- Trial name
- Lymvac-2 (NCT02677155)
- Testing
- Radiotherapy, Rituximab, Autologous dendritic cells
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Periodontal Disease
Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells
Periodontitis develops due to subgingival infection with specific microbial pathogen from dental plaque. The bacteria can activate immunoinflammatory mechanisms within the local periodontal tissues that lead to destruction of…
- Trial name
- NCT00162838
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00053196
- Testing
- anti-thymocyte globulin, G-CSF, busulfan
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Stage IV Colorectal Cancer, Curative Resection
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer
- Trial name
- COREVAX-1 (NCT02919644)
- Testing
- autologous dendritic cells loaded with autologous tumour homogenate, IL2
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Colorectal Carcinoma
Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients
Single arm Phase I/II multicentric open labeled, with translational sub-study, of avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients..
- Trial name
- AVEVAC (NCT03152565)
- Testing
- Avelumab
- Where
- 8 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Malignant Melanoma
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
PRIMARY OBJECTIVES: Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs . SECONDARY OBJECTIVES:Determine immunological response to the vaccine (induction of specific T-cell response) and…
- Trial name
- NCT01278940
- Testing
- Dendritic Cells (DC) malignant melanoma, IL-2
- Volunteers
- 31 people
- Sponsor
- Oslo University Hospital
Prostate Cancer
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
20 patients with invasive castration resistant prostate cancer and radiologically verified metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell based immunotherapy.
- Trial name
- CryoIT (NCT02423928)
- Testing
- Dendritic cell based cryoimmunotherapy, Cyclophosphamide, ipilimumab
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Alden Cancer Therapy II
Dendritic Cell Deficiency
Sargramostim for Myeloid Dendritic Cell Deficiency
Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation.
- Trial name
- NCT01871467
- Testing
- Sargramostim
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
DLBCL - Diffuse Large B Cell Lymphoma
ImmunoMRI for Assessment of Tumor-associated Macrophages
About 35% of patients with a type of blood cancer called diffuse large B-cell lymphoma don't respond well to standard treatment or their cancer comes back.
- Trial name
- NCT07066436
- Testing
- MRI contrast-enhancing agents
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Multiple Myeloma
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM).
- Trial name
- NCT03782064
- Testing
- Nivolumab, DC/myeloma fusions/GM-CSF
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Ovarian Epithelial Cancer
Safety of Active Immunotherapy in Subjects With Ovarian Cancer
The purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic…
- Trial name
- NCT01456065
- Testing
- Procure
- Where
- 5 sites in Austria, Hungary
- Volunteers
- 15 people
- Sponsor
- Life Research Technologies GmbH
Neoplasms
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
According to a survey from Department of Health in 2004, cancer has been the leading cause of death in the Taiwan area. In 2004, people died of cancer, accounting for 27.2 percent of all deaths.
- Trial name
- NCT00521287
- Testing
- Immune profiling and DC vaccine
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory…
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05020678
- Testing
- NKX019
- Where
- 6 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Nkarta, Inc.
Cancer
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who…
- Trial name
- NCT00949052
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt-Ingram Cancer Center